For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

MER-XMT-1536-1/GOG-3048

Trial Overview

Official Title

A Phase 1B/2, First-In-Human, Dose Escalation And Expansion Study Of XMT-1536 In Patients With Solid Tumors Likely To Express NAPI2B

Study Purpose

The purpose of testing your tumor samples for levels of the NaPi2b protein or RNA is to evaluate whether this testing can be used as a tool to help determine if a patient’s cancer will respond to treatment for future patients prior to their dosing with XMT-1536.

Diagnosis

Patients who have been diagnosed with one of the following NaPi2b (sodium-dependent phosphate transporter)-expressing cancers: • Platinum-resistant high-grade serous ovarian cancer Prior treatments have not worked (or have stopped working) against your cancer and it has continued to grow.

Eligibility

Platinum resistant ovarian cancer (1-3 prior lines) or any recurrent ovarian cancer patient who has had 4 or more prior therapies.

Must be high-grade serous.

Measurable disease required.

No more than 2 prior lines containing taxane.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Open-Label XMT-1536 every 28 days until progression

For more information, visit ClinicalTrials.gov

 

Key Participation Requirements
Gender
Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase IB
Methodist Health System Trial Code
MER-XMT-1536-1/GOG-3048
Related Specialties